https://www.**********.co.uk/articles/tekcapital-fy21-results-preview-cbd523a ".. recent weakness in the price presents an interesting entry point for all shareholders.."
on Monday. Net profit HY1 FY2021 was US$40.5m and sp back then was about 110p Net profit HY1 FY2022 will presumably be announced as US$24.1m (Q1+Q2 from previous RNSs) How will the market respond to that year on year decrease?
The trial will include multiple cohorts beginning with healthy subjects, followed by peanut allergic patients who will undergo skin prick tests, and then peanut allergic patients who will receive subcutaneous injections. The topline data from the Phase I PROTECT trial in adult patients is expected in H1 2023, earlier than the originally intended data readout of Q4 2023.
RE: M19 Landing Page/Home Page Updated5 Jan 2022 18:53
I'm a consumer, can I buy a COVID-19 Test? No, not right now. Medusa 19 Ltd is working with its partners to obtain the approvals needed for consumer use. As soon as these approvals are in place, we will update this site and give details of availability. https://www.medusa19.com/en/meduflow-rapid-antigen-test/
https://www.primarycaresupplies.co.uk/surescreen-covid-19-rapid-antigen-test/ "The UK government has secured 20 million British-manufactured rapid coronavirus (COVID-19) tests in a new contract with Derby-based test manufacturer SureScreen Diagnostics. These lateral flow antigen tests produce a result in under 30 minutes and are the first British tests to be validated in the laboratory by Public Health England (PHE)."
"This has been a very successful half year, characterised by substantial cashflow growth and accelerating investment deployment. Cash revenue is up 78% from the prior period to £7.8 million, and we have delivered a 58% increase in free cashflow to £4.6 million. This positive performance has been driven mainly by our team's rapid execution of new royalty agreements which has seen us invest over £23 million into three new royalty partners during the period.
"This strong trading performance makes me confident that Duke will exceed the market's expectations for the 12 months ended 31 March 2022. Since the resumption of its cash dividend, Duke has increased its dividend payment from 0.50 pence per share to 0.55 pence per share, with the prospect of higher dividend payments for shareholders in the future. This growth will be supported by entering into new royalty agreements and I am pleased to report that our pipeline is the strongest in our history. We expect to announce a range of new deployments in the coming weeks and months."
Leon Coetzer, Chief Executive Officer, commented: "Further significant progress has been made over recent months at both our South African and Zambian operations, as well as outside the African continent, with the collaboration with Cyprus based Caerus Mineral Resources...."
- £1.5m will be used to build inventory and progress product development for Lucyd, £0.5m will be used to expand inventory for Salarius and £0.5m will be used to provide CAPEX for Guident's remote monitoring and control centre.
Looking through recent holdings RNSs, the number of shares in issue, prior to today's 10.7mn, was 131mn. So dilution due to adding those 10.7mn was only around 8%
At about 23mins into this August 2021 interview https://www.youtube.com/watch?v=ocLSXWkLaRI "We are tracking a number of technologies for potential acquisition. Before we pull the trigger for our next technology acquisition to build our next technology portfolio company we want to see some more meaningful progress from our portfolio companies. " This gives the impression, before making another acquisition, either TEK aims to monetise at least one of their current portfolio companies, or they want to see the TEK sp moving up significantly before issuing more equity. Could be a combination of the two of course.